Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06872333 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Allo HSCT for High Risk Hemoglobinopathies

StatusRecruiting
PhasePhase 2
Started2024-11-19
View on ClinicalTrials.gov ↗

Amendment history

2026-06-01
Study Status, Arms and Interventions, Eligibility v2
Trial arms changed: 4 → 5
InterventionsAlemtuzumab (Drug), Busulfan (Drug), Cell Infusion (Biological), Cyclophosphamide (Drug), Fludarabine (Drug), Mycophenolate Mofetil (Drug)…→Alemtuzumab (Drug), Busulfan (Drug), Cell Infusion (Biological), Cyclophosphamide (Drug), Fludarabine (Drug), Mycophenolate Mofetil (Drug)…
Eligibility criteria+160 characters
[...] must have a negative pregnancy test (serum or urine) within 730 days of the start of treatment HIV Positiveinfection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation. Active, uncontrolled infection - infection that is stable or [...]
2026-03-10
Study Status v1
Re-verified, no change to tracked fields
2025-03-06
Original filing
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Trial Details
NCT Number NCT06872333
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Enrollment 62 participants
Start Date 2024-11-19
Primary Completion 2030-06-01 (estimated)
Study Completion 2032-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04